In 2019, Evotec acquired Just Biotherapeutics, an AI/ML antibody discovery ... AI-small molecule discovery spaces Compared to the small molecule AI drug discovery ecosystem, this space is evolving ...

AI models are able to design molecules that don’t even exist in nature. Some have proven effective as snake antivenom.

LinkedIn founder Reid Hoffman and Siddhartha Mukherjee, cancer researcher and author of the book “The Emperor of All Maladies ...

The proof-of-concept demonstrates the power of pairing AI with lab orchestration solutions to automate molecular screening ...

By leveraging its proprietary AI ... antibody mimics for therapeutic applications "Our interdisciplinary team is uniquely equipped to tackle the most complex challenges in drug discovery," said ...

Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...

Absci (NASDAQ:ABSI) recently achieved a few milestones in healthcare AI as it received a $20 million investment from AMD to support Absci’s AI-driven drug discovery initiatives. In addition ...

With the advent of artificial intelligence (AI), the industry witnessed a rapid transformation in early disease detection, genomic research, drug discovery, clinical processes, and treatment ...

We recently compiled a list of the Top 10 AI Stocks Dominating Wall Street. In this article, we are going to take a look at where Lantern Pharma Inc. (NASDAQ:LTRN) stands against the other AI stocks.

Manas AI, a full-stack, AI-driven company focused on discovering and advancing next generation medicines, launched today. By leveraging its proprietary AI-driven platform, its partnership with ...